

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

OFFICE OF
PESTICIDES AND TOXIC
SUBSTANCES

MEMORANDUM:

SUBJECT: Comments on Registrant Clarification Request
For a Red Cell Binding Study on Simazine.
Chem No 740

TO: Venus Eagle
Reregistration Branch
RRSD (H7508W)

FROM: Henry Spencer Ph.D. *Hand 5/21/92*
Review Section 3
Toxicology Branch 1
Health Effects Division (H7509C)

THRU: Karen Hamernik, Ph.D. *KH*
Acting Section Head
Review Section 3
Toxicology Branch 1
Health Effects Division (H7509C)

Karl Baetcke, Ph.D. *Karl Baetcke 5/22/92*
Chief
Toxicology Branch 1
Health Effects Division (H7509C)

CONCLUSIONS:

The need for an additional red cell binding study has been reconsidered and has been determined to no longer be needed in the review of Simazine for safety.

COMMENTS:

The Registration Standard for Simazine had requested that a red blood cell binding study be conducted as a special test. The initial request was predicated on the review of: 1. a metabolism study submitted to the Agency using C14 labelled Simazine in the rat and, 2. a metabolism study with Simazine presented in the open literature, and, 3. the occurrence of a measureable drop in red cell parameters in Simazine and other triazine studies of both dogs and rats.

Since the studies demonstrate a NOEL for hematologic effects at levels higher than the dose chosen for the NOEL of the chemical, and that there is a very adequate UF of much greater than 100 for this demonstrable effect in the rodent, Toxicology Branch considers it unnecessary to further test whether red cell binding occurs or not. Obviously, if it did, it would provide no additionally lower dose level than presently used on which to base an RfD.